Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin

Gastroenterology Research and Practice
Muhammed SheridSubbaramiah Sridhar

Abstract

Introduction. The risk of gastrointestinal (GI) bleeding with rivaroxaban has not been studied extensively. The aim of our study was to assess this risk in comparison to warfarin. Methods. We examined the medical records for patients who were started on rivaroxaban or warfarin from April 2011 to April 2013. Results. We identified 300 patients (147 on rivaroxaban versus 153 on warfarin). GI bleeding occurred in 4.8% patients with rivaroxaban when compared to 9.8% patients in warfarin group (p = 0.094). GI bleeding occurred in 8% with therapeutic doses of rivaroxaban (>10 mg/d) compared to 9.8% with warfarin (p = 0.65). Multivariate analysis showed that patients who were on rivaroxaban for ≤40 days had a higher incidence of GI bleeding than those who were on it for >40 days (OR = 2.8, p = 0.023). Concomitant use of dual antiplatelet agents was associated with increased risk of GI bleeding in the rivaroxaban group (OR = 7.4, p = 0.0378). Prior GI bleeding was also a risk factor for GI bleeding in rivaroxaban group (OR = 15.5). Conclusion. The incidence of GI bleeding was similar between rivaroxaban and warfarin. The risk factors for GI bleeding with rivaroxaban were the first 40 days of taking the drug, concomitant dual antiplatel...Continue Reading

References

Mar 8, 2005·Journal of Thrombosis and Haemostasis : JTH·E PerzbornA Straub
Oct 4, 2005·Clinical Pharmacology and Therapeutics·Dagmar KubitzaGeorg Wensing
Jan 18, 2006·Journal of Thrombosis and Haemostasis : JTH·B I ErikssonUNKNOWN ODIXa-HIP Study Investigators
Nov 15, 2006·British Journal of Clinical Pharmacology·Dagmar KubitzaMichael Zuehlsdorf
Jun 27, 2008·The New England Journal of Medicine·Bengt I ErikssonUNKNOWN RECORD1 Study Group
Jun 27, 2008·The New England Journal of Medicine·Michael R LassenUNKNOWN RECORD3 Investigators
Aug 22, 2008·Current Medical Research and Opinion·Dagmar KubitzaWolfgang Mueck
Feb 7, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·C WeinzD Lang
Jun 30, 2010·International Journal of Clinical Practice·J M Walenga, C Adiguzel
Oct 16, 2010·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Mihai GheorghiadePaul Burton
Dec 7, 2010·The New England Journal of Medicine·Rupert BauersachsSebastian Schellong
Apr 26, 2011·The Journal of Pharmacology and Experimental Therapeutics·Mark Jean GnothSteffen Sandmann
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Mar 28, 2012·The New England Journal of Medicine·Harry R BüllerAnnelise Segers
Jun 6, 2012·Circulation Journal : Official Journal of the Japanese Circulation Society·Masatsugu HoriUNKNOWN J-ROCKET AF study investigators
Dec 12, 2012·Circulation Journal : Official Journal of the Japanese Circulation Society·Masatsugu HoriUNKNOWN J-ROCKET AF study investigators
Jan 12, 2013·British Journal of Clinical Pharmacology·Wolfgang MueckMichael Becka
Feb 8, 2013·The New England Journal of Medicine·Alexander T CohenUNKNOWN MAGELLAN Investigators

❮ Previous
Next ❯

Citations

Mar 21, 2017·Expert Review of Cardiovascular Therapy·Gonzalo Barón-EsquiviasMarcelo Sanmartín Fernandez

❮ Previous
Next ❯

Software Mentioned

Excel
SAS

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.